Abstract: A watermark image may be generated that includes a first set of encoded pixels each of which is assigned a first transparency value and a second set of encoded pixels each of which is assigned a second transparency value, the second transparency level being different from the first transparency level. The encoded pixels may be distributed among a set of blank pixels such that each encoded pixel neighbors one or more blank pixels in the watermark image, and in particular at least two blank pixels in the watermark image. Herein, each blank pixel may be assigned the second transparency value. The watermark image may be overlaid and blended over a background source image to create an encoded source image. A decoder system may recover encoded information from the encoded source image.

Abstract: Systems and techniques are described for depth sensing. For example, a method can include obtaining a first depth image of a scene. The first depth image of the scene is associated with a first illumination configuration including illuminating the scene with a first type of illumination. The method can include obtaining a second depth image of the scene, wherein the second depth image is associated with a second illumination configuration, different from the first illumination configuration. The second illumination configuration includes illuminating the scene with a second type of illumination. The method can include determining, based on the second depth image, multipath interference (MPI) associated with the first depth image. The method can further include generating based on determining the MPI associated with the first depth image an adjusted depth image including one or more pixels from the first depth image and one or more adjusted pixels.

Abstract: Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a ?2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.

Abstract: Various embodiments relate to an electrochromic (EC) device that is structured with surface contour features arranged according to a randomized pattern. For example, one or more conductive layers of an EC device may be structured with such surface ablations. In some embodiments, the randomized ablation pattern may comprise a randomized variation in one or more geometrical characteristics of a group of segments. In some examples, the geometrical characteristic(s) may include a distance characteristic, an orientation characteristic, and/or a shape characteristic, etc. According to various embodiments, the randomized ablation pattern may be configured to reduce diffraction and/or scatter of light incident on the surface ablations as compared to some other ablation patterns.

Abstract: A method of operating an electrochromic device comprising: coupling a logic device to the electrochromic device; applying a voltage to the electrochromic device; receiving a current from the electrochromic device in response to the provided voltage; and with the logic device, determining an exact operating condition of the electrochromic device from the received current. A method of operating a plurality of electrochromic devices comprising: adjusting a frequency of voltage applied to the plurality of electrochromic devices, wherein each of the plurality of electrochromic devices is adjusted by a different frequency; measuring a duration of time required to change tint states of each of the electrochromic devices; and identifying a location of each of the plurality of electrochromic devices in response to the measured duration of time required to change the tint states of each of the electrochromic device.

Abstract: Provided herein are surfactant compounds that can be used to aid in preparation of protein samples for analysis, for example by mass spectrometry.

Abstract: The present invention relates to a negative electrode material comprising a hydrogen storage alloy and a coating layer on a surface of the hydrogen storage alloy. Based on the mass of the negative electrode active material, a content of the coating layer is no less than 2 wt %. The coating layer comprises a component shown by a general formula LnFx, wherein Ln is one element selected from the group consisting of La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Y, and Sc. The present invention also relates to a preparation method for the above-described negative electrode material. The present invention also relates to a nickel-metal hydride secondary battery using this negative electrode material.

Abstract: The present disclosure provides a chimeric antigen receptor (CAR) specific for albumin. The present disclosure also provides compositions comprising the CAR, polynucleotides encoding the CAR, vectors comprising a polynucleotide encoding the CAR, engineered cells comprising the CAR, and method using the same.

Abstract: The present invention relates to a positive electrode material comprising a core material and a coating layer coated on the surface of the core material, the core material comprises nickel hydroxide, and the coating layer comprises a tetravalent cobalt compound; and based on the weight of the coating layer, the content of the tetravalent cobalt compound is no less than 45 wt %. The present invention also relates to a preparation method for the positive electrode material. The present invention further relates to an alkaline secondary battery containing the positive electrode material.

Abstract: A displacement detector may include a substrate and a membrane having an inner surface facing the substrate. A mounting area may be arranged to fix the membrane along at least part of the perimeter of the membrane, wherein the mounting area, the inner surface and the substrate enclose a back volume. An acoustic compliance of the back volume may be arranged to be the same or larger than an acoustic compliance of the membrane. An optical sensor may be configured to generate a sensor signal indicative of a displacement of the membrane.

Abstract: Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist.

Abstract: Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism and myeloproliferative disorders using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: Provided a chimeric anti-drug antibody receptor (CADAR) specific for anti-drug-antibody-based B cell receptor (BCR), the anti-drug antibody is induced by a therapeutic anti-TNF-alpha monoclonal antibody. Also provided compositions comprising the CADAR, polynucleotides encoding the CADAR, vectors comprising a polynucleotide encoding the CADAR, engineered cells comprising the CADAR, and method using the same.

Abstract: Provided is a chimeric alloantibody receptor (CALAR) specific for alloantibody-based B cell receptor (BCR), wherein the alloantibody is specific for an Rh factor. Also provided are compositions comprising the CALAR, polynucleotides encoding the CALAR, vectors comprising a polynucleotide encoding the CALAR, engineered cells comprising the CALAR, and method using the same.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a ?2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.

Abstract: A game summary may be produced using an event log of in-game events and corresponding game content based on game data associated with a gameplay session(s). The event log may include metadata that indicates times of in-game events and associations between in-game events and game content items that capture the in-game events. A user may interact with in-game events with temporal context, allowing for more informed selections and a better understanding of the gameplay session. Using the event log, a game summary may provide such features as a timeline to convey relative timing of in-game events, a list of in-game events, a map of a virtual environment of the game that is temporally annotated based on in-game events, game status information, and statistical and performance information. A game summary may show trends over time and/or game sessions and convey information for selected sets of players, such as teams.